MedX Health Corp. Announces Brokered Private Placement

MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX) announces the
engagement of Trapeze Capital Corp., as lead agent (the "Agent"), to raise gross
proceeds of up to $2.0 million, from accredited investors, on a reasonable
efforts basis through a private placement of Units, with each Unit comprised of
one Common Share and one Common Share Purchase Warrant ('Warrant") (the
"Offering") at $0.10 per Unit. Each Warrant will entitle the holder to purchase
one Common Share during the period ending two years from the date of issue, at
an exercise price of $0.20.  


Closing of the Offering will be subject to receipt of subscriptions and also a
number of conditions, including the receipt of all relevant regulatory and other
consents and approvals, including that of the TSX Venture Exchange, as well as
the negotiation and execution of certain documentation, including an agency
agreement between the Agent and MedX. Closing of the Offering is expected to
take place in late February. 


At closing, MedX will pay the Agent a cash commission equal to 8% of the
aggregate proceeds of the Units sold, and will issue broker warrants to the
Agent to acquire that number of common shares equal to 8% of the number of
common shares that comprise the Units sold by the agent under the Offering. Each
broker warrant will be exercisable at $0.20 per share for a period of two years
after closing. As well, MedX will pay the Agent's reasonable expenses incurred
in connection with the Offering. 


The net proceeds from sale of the Units will be used for the expansion of
marketing efforts of the Company's products, and for general working capital
purposes. All securities issued in conjunction with the Offering will be subject
to a four-month and one day hold period under applicable securities laws and the
policies of the TSX Venture Exchange. 


About MedX 

MedX is headquartered in Mississauga, Ontario (Toronto), and is a global leader
in the design, manufacturing and distribution of quality low level laser and
light therapy technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine, providing
patients with drug free and non-invasive treatment of tissue damage and pain.
MedX laser and light products are FDA approved, Health Canada cleared, and CE
Mark approved for use in North America as well as the European Union. MedX's
products include SIMSYS(TM) and MoleMate(TM), which are approved by Health
Canada, and available to Canadian physicians and dermatologists, are FDA
approved for use in the USA and are currently under review for CE approval for
use in Europe, the UK, and Australia, as an optical biopsy that uses patented
technology featuring a hand-held scanner device designed for clinical use that
utilizes light to view beneath suspicious moles or lesions in a pain free,
non-invasive manner, creating images in real-time for physicians and
dermatologists to evaluate all types of moles or lesions within seconds. For
more information log onto: www.simsys-molemate.com. For a complete profile of
MedX and its products visit www.medxhealth.com.


This press release does not constitute an offer of any securities for sale. This
press release contains certain forward-looking statements within the meaning of
applicable Canadian securities legislation. These forward-looking statements
involve certain risks and uncertainties that could cause actual results to
differ, including, without limitation, the company's limited operating history
and history of losses, the inability to successfully obtain further funding, the
inability to raise capital on terms acceptable to the company, the inability to
compete effectively in the marketplace, the inability to complete the proposed
acquisition and such other risks that could cause the actual results to differ
materially from those contained in the company's projections or forward-looking
statements. All forward looking statements in this press release are based on
information available to the company as of the date hereof, and the company
undertakes no obligation to update forward-looking statements to reflect events
or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
MedX Health Corp.
Robert von der Porten
President and CEO
905 670 4428
investor@medxhealth.com
www.medxhealth.com
Medx Health (TSXV:MDX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024